Co-Create GLP-1 Companion Products
ADM can help you capture your share of the growing GLP-1 support market. Reach out and partner with us today to develop companion products using our specialized portfolio of ingredients and full-formula expertise.
GLP-1 Stats
Insights show that the market for products designed to support consumers on GLP-1 weight loss meds stands to grow in the coming years.
Potential consumers
30% of the global population is overweight, with 60% seeking weight management benefits from food.1
Future market state
By 2030, 30 million adults in the U.S. may potentially be treated with GLP-1 medications for weight loss.3
Current consumer base
Approximately 15% of U.S. adults are currently using or are considering using a GLP-1 medication for weight loss.2
Key Ingredients and Expertise to Support GLP-1 Users
As consumer demand rises for GLP-1 weight management meds, the need for nutrition support solutions will also dramatically increase. Our global team of experts can provide the science-backed ingredients and formulation know-how to help you develop GLP-1-focused products across food, beverage, and dietary supplement applications.
How ADM Can Help You Support GLP-1 Consumer Needs:
Support for Consumers During GLP-1 Use
Leverage our science-backed ingredients to develop products that meet the needs of consumers taking GLP-1 medications for weight loss.
Muscle Health
Muscle mass retention is a priority for GLP-1 users. When dieting, 20 % to 40% of typical weight loss comes from muscle mass.4 Our plant-based proteins can help support muscle health in a variety of applications, such as supplements, ready-to-eat meals, and snacks.
GI Comfort
With more than 40% of GLP-1 users reporting nausea and more than 20% reporting diarrhea and vomiting,5 gut health often plays a large role in the GLP-1 weight management journey. We can help you develop products like supplements, yogurt, and more that contain our science-backed biotics and fiber solutions to help support GI comfort.
Hydration
GLP-1 consumers may experience “thirst satiation,” leading to reduced fluid consumption.6,7 We've got the flavors and natural sweetening solutions you need to offer customers reduced-sugar hydration options.
Support for Consumers After GLP-1 Use
During the six-month period after stopping or reducing GLP-1 use, consumer needs may change — and our comprehensive ingredient portfolio can still offer the support they're looking for.
Satiety
When consumers discontinue or reduce the use of GLP-1s, the “food noise” that is dampened can likely return, increasing the importance of dietary levers to induce satiety.8 ADM can help you develop satiety support products with our wholesome fiber and plant-based protein solutions.
Weight Regain Management
Two-thirds of the weight lost from GLP-1 meds is regained within one year.9 But thanks to our reduced-sugar formulations and fiber and protein solutions available across multiple applications, we're ready to help you support GLP-1 consumers' long-term goals.
ADM: Your Expert Development Partner
Partnership
We’ll collaborate with you to create the right formulations for your customers, ensuring that each product is tailored to their needs and your specifications.
Market insights
Thanks to our constant research around the globe, we’ve got our finger on the pulse of what GLP-1 consumers want now and how to support them throughout their weight management journeys.
Broad Portfolio of Science-Backed Ingredients
Working with ADM gives you access to a vast array of ingredients backed by clinical studies and scientific research, including proprietary ingredients to help support muscle health and GI comfort, reduce sugar, and more.
Innovation and Formulation Expertise
With a legacy of leadership in unique product solutions and state-of-the-art development techniques, we can help you bring custom GLP-1 companion products to market.
Contact us
Request a consultation with a formulation expert to learn how we can help you create products to support GI comfort, muscle health, hydration, and more for consumers engaging with anti-obesity medications.
Enter a valid email address.
*Must complete form input fields before continuing.
References
1. World Health Organization. Obesity and overweight. March 1, 2024; OutsideVoice(SM) Fiber Consumer Study, 2019. 2. Civic Science. Ozempic Tracker Highlights: GLP-1 Users Pull Back on Dining Out and Exercising, April 23, 2024. 3. Goldman Sachs, October 2023. 4. World Health Organization. Obesity and overweight. June 9, 2021. 5. A Stock Investor's Guide to Navigating Weight Loss. Bloomberg. September 16, 2023. 6. World Obesity Foundation, Global prevalence of obesity. 7. Barclays. Weight-loss drugs through a global consumer lens. August 31, 2023. 8. Khera & Powell-Wiley. (2023) NEJM. 389:2287-8. 9. Powell-Wiley, et al. (2021) Circulation. 143(21):e984-1010.
This communication is intended for B2B use and no statements are meant to be perceived as approved by regulatory authorities. Local regulations must be reviewed to confirm permissibility of ingredients and claims for each food category.